HighPoint Advisor Group LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

HighPoint Advisor Group LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,945 shares of the medical device company’s stock, valued at approximately $427,000.

A number of other large investors have also made changes to their positions in DXCM. Versant Capital Management Inc acquired a new position in DexCom during the fourth quarter worth $25,000. Private Trust Co. NA raised its holdings in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC boosted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in DexCom during the fourth quarter worth about $38,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on DXCM. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Finally, Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 1.2 %

DXCM opened at $68.14 on Thursday. The business has a fifty day moving average price of $81.24 and a 200 day moving average price of $77.04. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $141.99. The stock has a market capitalization of $26.63 billion, a price-to-earnings ratio of 47.65, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.